TITLE

Hypertension

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS36
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `The effects of fenofibrate and pravastatin in the DAHL salt-sensitive rat,' by T.W. Wilson, M. Alonso-Galacia et al from the University of Saskatchewan. Salt-sensitive hypertension.
ACCESSION #
9708236224

 

Related Articles

  • Fenofibrate.  // Reactions Weekly;3/14/2009, Issue 1243, p22 

    The article describes the case of a woman who developed acute cholestatic hepatitis during treatment with fenofibrate for hyperlipidaemia. She had a history of hyperlipidaemia as well as hypertension for 15 years and type 2 diabetes mellitus. She presented with worsening jaundice, pruritus,...

  • Fenofibrate.  // Reactions Weekly;1/5/2008, Issue 1183, p15 

    The article describes the case of a 42-year-old woman who developed rhabdomyolysis and acute renal failure during treatment with fenofibrate. The patient was administered fenofibrate and candesartan cilexetil/hydrochlorothiazide for hypertension and hyperlipidaemia. She was later hospitalised...

  • Antihyperlipidemic.  // Geriatrics;May98, Vol. 53 Issue 5, p25 

    Reports on the approval of the drug, oral fenofibrate, micronized (Tricor) as an adjunct to diet for adults that need treatment for high elevations of serum triglycerides who are at risk for Pancreatitis. Details on the drug; Side effects of the drug; Instructions for safe use of the medication.

  • Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension. Lee, Dexter L.; Wilson, Justin L.; Duan, Rong; Hudson, Tamaro; El-Marakby, Ahmed // PPAR Research;2011, Special section p1 

    Peroxisome proliferator-activated receptor-alpha (PPAR-α) activation by fenofibrate reduces blood pressure and sodium retention during DOCA-salt hypertension. PPAR-α activation reduces the expression of inflammatory cytokines, such as interleukin-6 (IL-6). Fenofibrate also induces...

  • Rosuvastatin interaction.  // Reactions Weekly;8/27/2005, Issue 1066, p10 

    Discusses research being done on the effect of concomitant therapy with rosuvastatin and fenofibrate on a woman wit a history of hypercholesterolaemia and hypertension. Reference to a study by J. H. e. Ireland et al, published in the June 2005 issue of the "Annals of Internal Medicine" journal;...

  • Additive Beneficial Effects of Fenofibrate Combined With Candesartan in the Treatment of Hypertriglyceridemic Hypertensive Patients. Kon Koh, Kwang; Quon, Michael J.; Seung Hwan Han; Wook-Jin Chung; Jeong Yeal Ahn; Jeong-A Kim; Yonghee Lee; Eak Kyun Shin // Diabetes Care;Feb2006, Vol. 29 Issue 2, p195 

    OBJECTIVE -- Mechanisms underlying fibric acid and angiotensin 11 type 1 receptor blocker therapies differ. Signaling from peroxisome proliferator-activated receptor α may cross-talk with the angiotensin II system. We investigated vascular and metabolic responses to these therapies either...

  • Paradoxical Decrease in High-Density Lipoprotein Cholesterol with Fenofibrate: A Quite Rare Phenomenon Indeed. Mombelli, Giuliana; Pazzucconi, Franco; Bondioli, Alighiero; Zanaboni, AnnaMaria; Gaito, Sabrina; Calabresi, Laura; Sirtori, Cesare R. // Cardiovascular Therapeutics;Jun2010, Vol. 28 Issue 3, p153 

    Some recent clinical reports have suggested that paradoxical decreases in high-density lipoprotein cholesterol (HDL-C) levels after fenofibrate treatment may be quite common. These appear to occur mainly in patients with combined fibrate/statin therapy and possibly in those with low baseline...

  • Fenofibrate.  // Reactions Weekly;2/6/2010, Issue 1287, p21 

    The article describes the case of a woman who developed rhabdomyolysis while being treated with fenofibrate for dyslipidemia.

  • Fenofibrate.  // Reactions Weekly;10/27/2012, Issue 1425, p18 

    The article describes the case of a 47-year-old woman who developed acute hepatitis with microvesicular steatosis after receiving fenofibrate for hyperlipidaemia.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics